Nano Drug Delivery for Cancer Therapy

Prof. Firdos Alam Khan is a chairman of the Department of Stem Cell Biology, Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia. In addition to his research work, he has been teaching (cell physiology and biochemistry and stem cell biology and regenerative medicine) courses to MSc students. Prof. Khan has done his Ph.D. degree in zoology with a neuroscience specialization from Nagpur University, India.  Over the past 26 years, Prof. Khan has been involved in teaching various courses such as cell biology, pharmacology, business of biotechnology, biomedicine, cell & tissue engineering, and bioethics-IPR to undergraduate and postgraduate students. Prof. Khan worked with Manipal Academy of Higher Education, Dubai Campus, United Arab Emirates as a professor and chairperson, School of Life Sciences. Prof. Khan did his first postdoctoral fellowship from the National Centre for Biological Sciences, Bangalore, India, anda second postdoctoral fellowship from Massachusetts Institute of Technology (MIT), Cambridge, USA. Professor Khan has also worked with the Reliance Life Sciences as a Research Scientist in the Stem Cell Research Laboratory. Prof. Khan has been granted 8 US patents and published 5 US patents. Prof. Khan has published more than 119 research papers in peer-reviewed journals.

• Ch 1 Significance of nano-drug delivery in cancer therapy, application of nanoparticles in overcoming drug resistance, targeted therapy, and Immunotherapy.- Ch 2 Synthesis of different types, shapes, and sizes of nanocarriers using synthetic and biological approaches.- Ch 3 Synthesis of nanocarriers loaded with anti-cancer drugs by using functionalization or conjugations, encapsulation methods.- Ch 4 Nano-Drug Carriers for Chemotherapeutic Agents Delivery in Cancer Disease Treatment.- Ch 5 Testing Of Nanocarriers Loaded with Chemotherapeutic Agents in the Animal Models of Cancers – Preclinical Trials for Efficacy and Safety Profiling of Nanocarriers.- Ch 6 Testing Of Nanocarriers Loaded With Chemotherapeutic Agents In The Animal Models Of Cancers – Preclinical Trials For Efficacy And Safety Profiling Of Nanocarriers.- Ch 7 Nanocarriers-Based Products In The Market, Fda Approval, Commercialization Of Nanocarriers, and Global Market.- Ch 8 Limitations of Nanocarriers Such as Cell and Tissue Toxicity, Genotoxicity, Scale-Up of Nanomaterials.- Ch 9 Health And Environmental Hazards Associated With The Synthesis Of Nanomaterials-Respiratory Diseases, Government Regulations, Ethical Issues.- Ch 10 Future trends and innovation in nano drug delivery for cancer therapy, application of siRNA (nanoparticle-based RNA) therapy, Ultrasound linked nano-cancer therapeutics, and application of exosomes-based cancer therapy.